Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Paracetamol (acetaminophen) overdose is a common medical emergency. The decision to treat with acetylcysteine is predominately based on the dose of drug ingested and a timed blood paracetamol concentration. These risk markers are used because most patients present to hospital soon after overdose, before hepatotoxicity can be excluded using current biomarkers such as serum alanine aminotransaminase activity (ALT). To improve patient stratification, sensitive liver-specific and mechanism-based biomarkers are in development 1-3. In a recent study we demonstrated that the liver-enriched microRNA, miR-122, and the necrosis marker proteins high-mobility group box 1 (HMGB1) and keratin-18 (K18) identified hepatotoxicity on hospital admission with areas under their respective receiver operator curves >90% and negative predictive values >95% 1. Here we present a case that demonstrates their potential utility. A 25-year-old man attended the Royal Infirmary of Edinburgh 4.5 h after a single Co-codamol overdose (60–70 tablets, total 30–35 g paracetamol/480–560 mg codeine). Blood was drawn 4.5 h after overdose and the paracetamol concentration was 107 mg l−1 (Table 1). The patient was deemed at low risk of hepatotoxicity applying the criteria that were standard UK practice at that time 4 and, therefore, the paracetamol concentration was interpreted using the '200-line' on the UK paracetamol treatment nomogram (line starting at 200 mg l−1 at 4 h post-ingestion). According to the UK guidance used at the time of presentation, acetylcysteine treatment was not indicated and the patient was discharged after psychiatric review. The patient returned to hospital 43 h after overdose because he had been vomiting and felt lethargic. Repeat blood tests (43 h post-overdose) demonstrated hepatotoxicity with coagulopathy (Table 1). The patient was immediately treated with intravenous acetylcysteine and recovered fully. ALT (U l−1) (ULN 50) miR-122 (let-7d normalized) (ULN 5.2) HMGB1 (ng ml−1) (ULN 0.9) Necrosis K18 (U l−1) (ULN 480) Retrospectively, biomarkers were measured (by a researcher blind to the patient's data) in the patient's first presentation sample (taken 4.5 h after overdose) and hepatotoxicity was unambiguously reported (Table 1). MiR-122 is a liver-enriched microRNA that is released into the circulation following paracetamol-induced hepatotoxicity. Both rodent and human studies demonstrate it is elevated early, when ALT is still normal 1, 3, 5. At 4.5 h after overdose in this patient, miR-122 was elevated 50-fold above the upper limit of normal (ULN). HMGB1 and K18 are proteins released by necrotic cells that are elevated in the circulation of rodents and humans with paracetamol toxicity 2, 6. In this patient they both reported toxicity on first hospital presentation (approximately 8-fold above ULN). At the time of first presentation to hospital, the UK guidelines were correctly applied and the patient was not treated. This misclassification may reflect the patient having increased susceptibility to hepatotoxicity, the time of overdose being earlier than reported, drug absorption being delayed by codeine or a second overdose after first discharge from hospital. However, had the new biomarkers been available toxicity would have been identified at first presentation. Since this case, the UK guidelines have changed and a single '100-line' (line starting at 100 mg l−1 at 4 h post-ingestion) is used for treatment decisions in all patients, meaning this case would now be correctly classified as needing treatment. However, this lowering of the treatment threshold is likely to result in increased hospital bed occupancy and overall financial cost, for only marginal benefits 7. Adoption of these biomarkers into clinical practice could target treatment to patients at elevated risk of hepatotoxicity. In North America, Australia and New Zealand, where a '150-line' is used (line starting at 150 mg l−1 at 4 h post-ingestion), this patient would still not be treated. This case report demonstrates the potential of new blood biomarkers for hospital front door stratification. This may improve patient identification for trials of new management pathways, facilitate earlier, safe, patient discharge and/or identify the rare patient with hepatotoxicity missed by current biomarkers. All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., & Park, B. K. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp235 · Cited by 223
Self-citation
Cited by
The past and present of serum aminotransferases and the future of liver injury biomarkers
McGill, M. R. (2016) · EXCLI journal · doi:10.17179/excli2016-800 · Cited by 487
Ramachandran, A., & Jaeschke, H. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679919 · Cited by 326
Church, R. J., Kullak‐Ublick, G. A., Aubrecht, J., Bonkovsky, H. L., Chalasani, N., Fontana, R. J., Goepfert, J. C., Hackman, F., King, N. M. P., Kirby, S., et al. (2019) · Hepatology · doi:10.1002/hep.29802 · Cited by 231
Dear, J. W., Clarke, J. I., Francis, B., Allen, L., Wraight, J., Shen, J., Dargan, P. I., Wood, D., Cooper, J., Thomas, S. H. L., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30266-2 · Cited by 123
Self-citationClarke, J. I., Dear, J. W., & Antoine, D. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1160057 · Cited by 46
Self-citation
Metadata
- Authors
- Dear, J. W., Antoine, D. J., Starkey‐Lewis, P., Goldring, C. E., & Park, B. K.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2014-04-22
- Volume
- 77
- Issue
- 5
- Pages
- 904-905
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2108107515
- Cited by
- 53
- References
- 2
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.